Identification of β-III-spectrin actin-binding modulators for treatment of spinocerebellar ataxia
P. Guhathakurta, R. T. Rebbeck, S. A. Denha, A. R. Keller, A. L. Carter, A. E. Atang, B. Svensson, D. D. Thomas, T. S. Hays, A. W. Avery
The paper develops an in vitro FRET assay to identify small molecule modulators of the L253P mutant β-III-spectrin actin-binding domain, identifying potential drug candidates for SCA5 treatment.
bioRxiv · Nov 8, 2022 · PreprintBiophysics